GlassScriptPhysician profile
Roberto Rios Valle
NPI 1710528567
$1,727.98
in general payments reported to CMS, 2019-2025
25 companies · $417 in 2025
The $417 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $422 · 2022: $149 · 2023: $365 · 2024: $375 · 2025: $417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,156.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $406.15 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Abbvie INC. | $219.05 | 2021-2025 | |
| Novo Nordisk INC | $138.83 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Nestle Healthcare Nutrition INC. | $125.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $99.85 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $95.08 | 2021-2025 | Farxiga, Airsupra |
| Teva Pharmaceuticals USA, INC. | $82.33 | 2025 | Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $60.90 | 2021-2023 | Abilify Maintena, Rexulti |
| Atland Pharmaceuticals, LLC | $56.50 | 2024 | Tolmetin Sodium, Orphenadrine Citrate, Aspirin and Caffeine |
| Sunovion Pharmaceuticals INC. | $49.98 | 2021 | |
| Axsome Therapeutics, INC. | $49.36 | 2024-2025 | Auvelity |
| Lundbeck LLC | $42.39 | 2022-2023 | Abilify Maintena |
| Abiomed | $34.89 | 2024 | Impella |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.77 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $31.87 | 2023-2025 | Trelegy Ellipta |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $30.09 | 2024 | Ragwitek, Odactra, Grastek |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.21 | 2022-2023 | Cycloset |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.63 | 2025 | |
| Exact Sciences Corporation | $21.42 | 2024 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $20.48 | 2025 | Gemtesa |
| Globus Medical, INC. | $20.43 | 2025 | Senza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.79 | 2021 | |
| Amgen INC. | $15.22 | 2024 | Otezla, Repatha |
| Cumberland Pharmaceuticals, INC. | $14.91 | 2025 | Kristalose |
| Allergan, INC. | $12.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Rios Valle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.